Showing results (21-30 of 420) with videos related to
Sort By:
Pageof 42
Annals of Internal Medicine|December 2, 2024
After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 yStephanos Vassilopoulos, Eleftherios MylonakisAnnals of Internal Medicine|April 1, 2024
In adults with post-COVID-19 conditions, a synbiotic preparation, SIM01, alleviated some symptoms at 6 moDeepa Gotur, Eleftherios MylonakisMedicine|May 9, 2020
Web search popularity, publicity, and utilization of direct oral anticoagulants in the United States, 2008-2018: A STROBE-compliant studyPanayiotis D Ziakas, Eleftherios MylonakisAMA Journal of Ethics|August 30, 2021
How Should Economic Analyses Inform Nosocomial Infection Control?Eleftherios Mylonakis, Panayiotis D ZiakasExpert Opinion on Pharmacotherapy|March 4, 2008
Epidemiology and management of cryptococcal meningitis: developments and challengesRead Pukkila-Worley, Eleftherios MylonakisExpert Opinion on Pharmacotherapy|May 23, 2007
Posaconazole: a new broad-spectrum antifungal agentDouglas S Kwon, Eleftherios MylonakisPLOS Digital Health|March 12, 2024
Public interest trends for COVID-19 and pandemic trajectory: A time-series analysis of US state-level dataPanayiotis D Ziakas, Eleftherios MylonakisClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2009
4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicityPanayiotis D Ziakas, Eleftherios MylonakisAnnals of Internal Medicine|April 4, 2022
In inpatients with COVID-19 who need supplemental oxygen, lenzilumab increased ventilation-free survivalVincent J Mariano, Eleftherios MylonakisCurrent Opinion in Microbiology|July 4, 2006
Using non-mammalian hosts to study fungal virulence and host defenseBeth Burgwyn Fuchs, Eleftherios MylonakisPageof 42